Phase II Cardiac Safety trial of liposomal pegylated doxorubicin in patients with breast cancer with non evidence of disease and previous exposition to Anthracyclines.

Trial Profile

Phase II Cardiac Safety trial of liposomal pegylated doxorubicin in patients with breast cancer with non evidence of disease and previous exposition to Anthracyclines.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 May 2011

At a glance

  • Drugs Doxorubicin liposomal (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 31 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top